Skip to main content
Clinical Trials/NCT07270289
NCT07270289Not yet recruitingNot Applicable

Total Intravenous Anesthesia (TIVA) Versus Inhalational Anesthesia at The End of Laparoscopic Obstetric Surgery Regarding Postoperative Nausea and Vomiting

Assiut University0 sites98 target enrollmentStarted: December 1, 2025Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
98
Primary Endpoint
Incidence of post operative neasea

Study Overview

Brief Summary

Postoperative nausea and vomiting (PONV) remain among the most common and distressing complications after general anaesthesia, with important consequences for patient comfort, satisfaction, recovery trajectories, and length of stay following surgery. The incidence of PONV is especially high after laparoscopic and gynaecological procedures due to patient- and procedure-related risk factors, making effective prevention and management a priority in perioperative care [5,8].

Anaesthetic technique is a recognized, modifiable determinant of PONV. Numerous clinical trials and randomized studies have demonstrated that the choice between propofol-based total intravenous anaesthesia (TIVA) and volatile inhalational maintenance can materially influence PONV incidence. Propofol-based TIVA has been repeatedly associated with lower rates of early and overall PONV compared with volatile agents in diverse surgical populations, supporting its role as an antiemetic strategy in addition to pharmacologic prophylaxis [1,2,4,9].

Trials specifically conducted in gynaecological and laparoscopic surgical populations report consistent reductions in nausea and vomiting with propofol maintenance compared with isoflurane or other volatile agents. These procedure-specific data are directly relevant to studies in gynecological laparoscopy, where baseline PONV risk is elevated and where anesthetic technique may yield a clinically meaningful reduction in patient morbidity [5,8,9].

Meta-analyses and systematic reviews pooling randomized controlled trials provide higher-level evidence that TIVA reduces the relative risk of PONV compared with volatile anaesthesia. Trial-sequential and pooled analyses estimate a clinically important risk reduction favoring TIVA, although effect sizes vary with study populations, prophylactic antiemetic regimens, and outcome time windows; these syntheses underpin the rationale for a targeted randomized comparison in the gynecological laparoscopic setting [2,4,10].

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Female, age 18-50 years.
  • Elective laparoscopic procedure under general anaesthesia with endotracheal intubation.
  • Expected surgical duration ≥ 30 minutes. -.Ability to consent and complete questionnaires

Exclusion Criteria

  • Pregnancy or lactation.
  • BMI ≥ 40 kg/m²; severe cardiopulmonary disease; hepatic/renal failure.
  • History of malignant hyperthermia or contraindication to study drugs.
  • Known allergy to propofol, , , sevoflurane/desflurane.

Outcomes

Primary Outcomes

Incidence of post operative neasea

Time Frame: 24 hours

Any episode of nausea (NRS ≥ 4/10 or requiring treatment)

incidance of postoperative vomting

Time Frame: 24 hours

any episode of vomiting/retching recorded at 0-2, 2-6, and 6-24 h; need for rescue antiemetic

Incidence of post operative neasea

Time Frame: 24 hours

Any episode of nausea (NRS ≥ 4/10 or requiring treatment)

incidance of postoperative vomting

Time Frame: 24 hours

any episode of vomiting/retching recorded at 0-2, 2-6, and 6-24 h; need for rescue antiemetic

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mohamed Ashraf kamel

Resident doctor at Anesthesia, Intensive Care and Pain Management

Assiut University

Similar Trials